ASX-listed BrainChip begins shipping production silicon for its Akida platform, signalling a major step forward in commercialising neuromorphic chips, but financial uncertainties persist as the company considers funding options amidst modest cash reserves.
BrainChip’s latest update has sharpened the contrast between technical progress and financial strain. The ASX-listed neuromorphic chip developer has begun shipping production silicon for its Akida platform and has added a defence order that gives the business a clearer commercial reference point. Yet the company’s cash position remains modest, losses continue, and management has said it is still considering funding options without announcing a concrete plan.
The company’s move from engineering samples to production shipments matters because it marks a shift from proof-of-concept activity towards repeatable manufacturing. In 2021, BrainChip said it had completed functionality and performance testing on its AKD1000 production chips, then later confirmed the start of volume manufacturing and the first shipment of chips from its manufacturing run. More recently, BrainChip said it had started commercial shipments of its AKD1500 reference chips, with production quantities going to customers while the devices undergo industrial and military qualification.
That history underlines the significance of the latest production phase. According to BrainChip’s own announcements, the architecture has now moved across several generations and manufacturing partners, including TSMC and GlobalFoundries, with each milestone presented as evidence that Akida can be built at commercial scale. The company has also said the chips are intended for edge AI applications where low power consumption and local processing are more important than cloud connectivity.
Even so, the commercial case still depends on whether those technical milestones turn into durable revenue. The latest half-year result showed sales rising, but from a very small base, while operating costs and development spending continued to outpace income. BrainChip has avoided offering firm financial guidance, arguing that bookings are uneven and difficult to forecast, although management has said it expects to reach cash flow neutrality eventually.
The funding issue is now central to how investors value the business. The company ended June with limited cash relative to its burn rate, and a financing facility it had relied on in earlier years expired during the half. Management told the earnings call that any capital decision would be assessed by the finance team and leadership before being taken to the board, leaving open the prospect of an equity raising in a market that has already priced in dilution risk.
At the same time, BrainChip is trying to broaden demand through defence, wearables and other battery-powered devices that can benefit from on-device inference. The company has pointed to customers and partners including Parsons, Raytheon and medical device developer Onsor, while also retaining a licensing model alongside chip sales. It says the long-term aim is to create a pipeline in which customers prototype with BrainChip silicon, then move into licences and royalties, but investors are likely to focus on signed revenue and cash generation before giving that strategy greater credit.
Disclaimer: This content is intended for informational purposes only. Readers are advised to exercise their own judgement, conduct due diligence, or consult a qualified expert before acting on any information provided.
